4SC AG today announced that Yakult Honsha Co. Ltd., 4SC’s development partner for resminostat in Japan, opens additional clinical centers in Japan and contributes patients to the RESMAIN study. Additionally, 4SC received a milestone payment.
by eazee-designstudio
Today Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS. The investment of up to $37,500,000 represents an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak.
Themis has established a Scientific Advisory Board (SAB) with the appointment of Christian W. Mandl, Ph.D., MD, W. Paul Duprex, Ph.D., Stephen J. Thomas, MD and Nadia G. Tornieporth, MD. The newly-formed SAB brings a wealth of experience in molecular virology, viral pathogenesis and vaccine development. The purpose of the SAB will be to advise Themis as it continues to develop its pipeline of urgently needed vaccines and immune system activation approaches.
Helios now provides its approx. 12,000 employed physicians with free access to the knowledge platform Amboss. This gives physicians the opportunity to receive answers to clinical questions on the basis of specific diagnostic and therapeutic recommendations at any time via their smartphone or computer.
Immatics today announced the appointment of Thomas Ulmer as Chief Financial Officer, effective April 1st, 2018. Thomas Ulmer joins Immatics from the Merck Group, where he is currently Chief Financial Officer of the Allergopharma Business Unit.
Themis announced the close of a Series C financing round led by Global Health Investment Fund (GHIF) as a new investor in the company. Glenn Rockman, Partner at GHIF, will join Themis’ Supervisory Board. The Series C proceeds will be used to advance Themis’ clinical and pre-clinical vaccine development programs.
Today, Ambu A/S – a leader in the development, manufacture and marketing of single-use devices for hospitals – has agreed to acquire invendo medical GmbH for a purchase price of up to EUR 225m. invendo medical is a leading developer of sterile, single-use HD endoscopy products in the field of gastroenterology and gastrointestinal surgery.
Immatics today announced the completion of its Series E financing, raising $58 million.
Immatics today announced that it has initiated enrollment of patients into a Phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program.
MSD today announced the acquisition of Rigontec for up to US$553M
